Advertisement

Infections in Cirrhosis: A Guide for the Clinician

Published:February 16, 2021DOI:https://doi.org/10.1016/j.amjmed.2021.01.015

      Abstract

      Cirrhosis contributes significantly to morbidity and mortality worldwide. Infections in patients with cirrhosis are common and significantly impact health-related quality of life. As our understanding of immune dysfunction associated with cirrhosis grows and as rates of drug-resistant organisms increase, the management of infections in cirrhosis has become increasingly nuanced. In this review, we discuss the current understanding of cirrhosis-associated immune deficiency, review the most common infections in patients with cirrhosis, and highlight techniques for the general clinician in the prevention and treatment of infections in this high-risk population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arvaniti V
        • D'Amico G
        • Fede G
        • et al.
        Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.
        Gastroenterology. 2010; 139 (1256.e1-e5): 1246-1256
        • Dionigi E
        • Garcovich M
        • Borzio M
        • et al.
        Bacterial infections change natural history of cirrhosis irrespective of liver disease severity.
        Am J Gastroenterol. 2017; 112: 588-596
        • Schmidt ML
        • Barritt AS
        • Orman ES
        • Hayashi PH
        Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.
        Gastroenterology. 2015; 148: 967-977.e2
        • Tapper EB
        • Parikh ND
        Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study.
        BMJ. 2018; 362: k2817
        • Albillos A
        • Lario M
        • Alvarez-Mon M
        Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.
        J Hepatol. 2014; 61: 1385-1396
        • Krenkel O
        • Tacke F
        Liver macrophages in tissue homeostasis and disease.
        Nat Rev Immunol. 2017; 17: 306-321
        • Irvine KM
        • Ratnasekera I
        • Powell EE
        • Hume DA
        Causes and consequences of innate immune dysfunction in cirrhosis.
        Front Immunol. 2019; 10: 293
        • Wiest R
        • Lawson M
        • Geuking M
        Pathological bacterial translocation in liver cirrhosis.
        J Hepatol. 2014; 60: 197-209
        • Rimola A
        • Soto R
        • Bory F
        • Arroyo V
        • Piera C
        • Rodes J
        Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis.
        Hepatology. 1984; 4: 53-58
        • Jenne CN
        • Kubes P
        Immune surveillance by the liver.
        Nat Immunol. 2013; 14: 996-1006
        • Borzio M
        • Salerno F
        • Piantoni L
        • et al.
        Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study.
        Dig Liver Dis. 2001; 33: 41-48
        • Rimola A
        • García-Tsao G
        • Navasa M
        • et al.
        Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club.
        J Hepatol. 2000; 32: 142-153
        • Kim JJ
        • Tsukamoto MM
        • Mathur AK
        • et al.
        Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis.
        Am J Gastroenterol. 2014; 109: 1436-1442
        • Na SH
        • Kim EJ
        • Nam EY
        • et al.
        Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites.
        Scand J Gastroenterol. 2017; 52: 199-203
        • Runyon BA
        • AASLD Practice Guidelines Committee
        Management of adult patients with ascites due to cirrhosis: an update.
        Hepatology. 2009; 49: 2087-2107
        • Runyon BA
        Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis.
        Hepatology. 1990; 12: 710-715
        • Akriviadis EA
        • Runyon BA
        Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis.
        Gastroenterology. 1990; 98: 127-133
        • Soriano G
        • Castellote J
        • Alcarez C
        • et al.
        Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management.
        J Hepatol. 2010; 52: 39-44
        • Runyon BA
        • Hoefs JC
        Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid.
        Hepatology. 1984; 4: 447-450
        • Lahmer T
        • Brandl A
        • Rasch S
        • Schmid RM
        • Huber W
        Fungal peritonitis: underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis.
        PLoS One. 2016; 11e0158389
        • Gravito-Soares M
        • Gravito-Soares E
        • Lopes S
        • Ribeiro G
        • Figueiredo P
        Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis.
        Eur J Gastroenterol Hepatol. 2017; 29: 1010-1016
        • Lameirão Gomes C
        • Violante Silva R
        • Carrola P
        • Presa J
        Bacterial infections in patients with liver cirrhosis in an internal medicine department.
        GE Port J Gastroenterol. 2019; 26: 324-332
        • Fernández J
        • Navasa M
        • Gómez J
        • et al.
        Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
        Hepatology. 2002; 35: 140-148
        • Leber B
        • Spindelboeck W
        • Stadlbauer V
        Infectious complications of acute and chronic liver disease.
        Semin Respir Crit Care Med. 2012; 33: 80-95
        • Yan D
        • Chen Y
        • Lv T
        • et al.
        Clostridium difficile colonization and infection in patients with hepatic cirrhosis.
        J Med Microbiol. 2017; 66: 1483-1488
        • Smith EZ
        • Northup PG
        • Argo CK
        Predictors of mortality in cirrhosis inpatients with Clostridium difficile infection.
        J Clin Gastroenterol. 2018; 52: 747-751
        • Saab S
        • Alper T
        • Sernas E
        • Pruthi P
        • Alper MA
        • Sundaram V
        Hospitalized patients with cirrhosis should be screened for Clostridium difficile colitis.
        Dig Dis Sci. 2015; 60: 3124-3129
        • Boivin Z
        • Perez MF
        • Atuegwu NC
        • Anzueto A
        • Mortensen EM
        Impact of cirrhosis on pneumonia-related outcomes in hospitalized older veterans.
        Am J Med Sci. 2019; 357: 296-301
        • Viasus D
        • Garcia-Vidal C
        • Castellote J
        • et al.
        Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores.
        Medicine (Baltimore). 2011; 90: 110-118
        • Gustot T
        • Durand F
        • Lebrec D
        • Vincent JL
        • Moreau R
        Severe sepsis in cirrhosis.
        Hepatology. 2009; 50: 2022-2033
        • Piano S
        • Bartoletti M
        • Tonon M
        • et al.
        Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
        Gut. 2018; 67: 1892-1899
        • Khan FA
        • Fisher MA
        • Khakoo RA
        Association of hemochromatosis with infectious diseases: expanding spectrum.
        Int J Infect Dis. 2007; 11: 482-487
        • Barton JC
        • Acton RT
        Hemochromatosis and Vibrio vulnificus wound infections.
        J Clin Gastroenterol. 2009; 43: 890-893
        • Capron JP
        • Capron-Chivrac D
        • Tossou H
        • Delamarre J
        • Eb F
        Spontaneous Yersinia enterocolitica peritonitis in idiopathic hemochromatosis.
        Gastroenterology. 1984; 87: 1372-1375
        • Robins-Browne RM
        • Prpic JK
        Desferrioxamine and systemic yersiniosis.
        Lancet. 1983; 2: 1372
        • Barton JC
        • McDonnell SM
        • Adams PC
        • et al.
        Management of hemochromatosis. Hemochromatosis Management Working Group.
        Ann Intern Med. 1998; 129: 932-939
        • Witte DL
        • Crosby WH
        • Edwards CQ
        • Fairbanks VF
        • Mitros FA
        Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis.
        Clin Chim Acta. 1996; 245: 139-200
        • Pagliano P
        • Boccia G
        • De Caro F
        • Esposito S
        Bacterial meningitis complicating the course of liver cirrhosis.
        Infection. 2017; 45: 795-800
        • Lin YY
        • Shiau S
        • Fang CT
        Risk factors for invasive Cryptococcus neoformans diseases: a case-control study.
        PLoS One. 2015; 10e0119090
        • Maimone S
        • Saffioti F
        • Filomia R
        • et al.
        Elective endoscopic variceal ligation is not a risk factor for bacterial infection in patients with liver cirrhosis.
        Dig Liver Dis. 2018; 50: 366-369
        • Llach J
        • Elizalde JI
        • Bordas JM
        • et al.
        Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy.
        Gastrointest Endosc. 1999; 49: 214-217
        • Deibert P
        • Schwarz S
        • Olschewski M
        • Siegerstetter V
        • Blum HE
        • Rössle M
        Risk factors and prevention of early infection after implantation or revision of transjugular intrahepatic portosystemic shunts: results of a randomized study.
        Dig Dis Sci. 1998; 43: 1708-1713
        • Moon E
        • Tam MDBS
        • Kikano RN
        • Karuppasamy K
        Prophylactic antibiotic guidelines in modern interventional radiology practice.
        Semin Intervent Radiol. 2010; 27: 327-337
        • Cheruvattath R
        • Balan V
        Infections in patients with end-stage liver disease.
        J Clin Gastroenterol. 2007; 41: 403-411
        • Kim G
        • Kang SH
        • Kim MY
        • Baik SK
        Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis.
        PLoS One. 2017; 12e0186990
        • Gao W
        • Kong M
        • Yao J
        • et al.
        Changes in prealbumin and body mass index associated with T lymphocyte subsets and nutritional status in chronic hepatitis B and HBV-cirrhosis patients.
        Clin Lab. 2018; 64https://doi.org/10.7754/Clin.Lab.2018.180501
        • Tandon P
        • Raman M
        • Mourtzakis M
        • Merli M
        A practical approach to nutritional screening and assessment in cirrhosis.
        Hepatology. 2017; 65: 1044-1057
        • Plauth M
        • Bernal W
        • Dasarathy S
        • et al.
        ESPEN guideline on clinical nutrition in liver disease.
        Clin Nutr. 2019; 38: 485-521
        • Pimentel CF
        • Lai M
        Nutrition interventions for chronic liver diseases and nonalcoholic fatty liver disease.
        Med Clin North Am. 2016; 100: 1303-1327
        • Dam G
        • Vilstrup H
        • Andersen PK
        • Bossen L
        • Watson H
        • Jepsen P
        Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites.
        Liver Int. 2019; 39: 514-521
        • Bajaj JS
        • Cox IJ
        • Betrapally NS
        • et al.
        Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
        Am J Physiol Gastrointest Liver Physiol. 2014; 307: G951-G957
        • Lo WK
        • Chan WW
        Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis.
        Clin Gastroenterol Hepatol. 2013; 11: 483-490
        • Goel GA
        • Deshpande A
        • Lopez R
        • Hall GS
        • van Duin D
        • Carey WD
        Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression.
        Clin Gastroenterol Hepatol. 2012; 10: 422-427
        • Bajaj JS
        • Zadvornova Y
        • Heuman DM
        • et al.
        Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.
        Am J Gastroenterol. 2009; 104: 1130-1134
        • Deshpande A
        • Pasupuleti V
        • Thota P
        • et al.
        Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
        J Gastroenterol Hepatol. 2013; 28: 235-242
        • Huang KW
        • Kuan YC
        • Luo JC
        • Lin CL
        • Liang JA
        • Kao CH
        Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis.
        Eur J Intern Med. 2016; 32: 91-95
        • Min YW
        • Lim KS
        • Min B-H
        • et al.
        Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study.
        Aliment Pharmacol Ther. 2014; 40: 695-704
        • Dam G
        • Vilstrup H
        • Watson H
        • Jepsen P
        Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.
        Hepatology. 2016; 64: 1265-1272
        • Bajaj JS
        • Ratliff SM
        • Heuman DM
        • Lapane KL
        Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis.
        Aliment Pharmacol Ther. 2012; 36: 866-874
        • Campbell MS
        • Obstein K
        • Reddy KR
        • Yang YX
        Association between proton pump inhibitor use and spontaneous bacterial peritonitis.
        Dig Dis Sci. 2008; 53: 394-398
        • Terg R
        • Cascioto P
        • Garbe C
        • et al.
        Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study.
        J Hepatol. 2015; 62: 1056-1060
        • Garcia-Tsao G
        • Sanyal AJ
        • Grace ND
        • et al.
        Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.
        Hepatology. 2007; 46: 922-938
        • Reiberger T
        • Ferlitsch A
        • Payer BA
        • et al.
        Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
        J Hepatol. 2013; 58: 911-921
        • Schaper J
        • Wagner A
        • Enigk F
        • et al.
        Regional sympathetic blockade attenuates activation of intestinal macrophages and reduces gut barrier failure.
        Anesthesiology. 2013; 118: 134-142
        • Blasco-Algora S
        • Masegosa-Ataz J
        • Alonso S
        • Gutiérrez ML
        • Fernández-Rodriguez C
        Non-selective beta-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function.
        BMJ Open Gastroenterol. 2016; 3e000104
        • Serste T
        • Bourgeois N
        • Lebrec D
        • Evrard S
        • Devière J
        • Le Moine O
        Relationship between the degree of portal hypertension and the onset of spontaneous bacterial peritonitis in patients with cirrhosis.
        Acta Gastroenterol Belg. 2006; 69: 355-360
        • Senzolo M
        • Cholongitas E
        • Burra P
        • et al.
        beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
        Liver Int. 2009; 29: 1189-1193
        • Sersté T
        • Melot C
        • Francoz C
        • et al.
        Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.
        Hepatology. 2010; 52: 1017-1022
        • Kalambokis GN
        • Christodoulou D
        • Baltayiannis G
        • Christou L
        Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites.
        Hepatology. 2016; 64: 1806-1808
        • Bernard B
        • Grangé JD
        • Khac EN
        • Amiot X
        • Opolon P
        • Poynard T
        Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.
        Hepatology. 1999; 29: 1655-1661
        • Fernandez J
        • Navasa M
        • Planas R
        • et al.
        Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
        Gastroenterology. 2007; 133: 818-824
        • Saab S
        • Hernandez JC
        • Chi AC
        • Tong MJ
        Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.
        Am J Gastroenterol. 2009; 104 (quiz 1002): 993-1001
        • Ginés P
        • Rimola A
        • Planas R
        • et al.
        Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
        Hepatology. 1990; 12: 716-724
        • European Association for the Study of the Liver
        EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
        J Hepatol. 2010; 53: 397-417
        • Soriano G
        • Guarner C
        • Tomás A
        • et al.
        Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
        Gastroenterology. 1992; 103: 1267-1272
        • Fernandez J
        • Ruiz del Arbol L
        • Gómez C
        • et al.
        Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
        Gastroenterology. 2006; 131 (quiz 1285): 1049-1056
        • Singh N
        • Gayowski T
        • Yu VL
        • Wagener MM
        Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial.
        Ann Intern Med. 1995; 122: 595-598
        • Martin DK
        • Walayat S
        • Jinma R
        • Ahmed Z
        • Ragunathan K
        • Dhillon S
        Large-volume paracentesis with indwelling peritoneal catheter and albumin infusion: a community hospital study.
        J Community Hosp Intern Med Perspect. 2016; 6: 32421
        • Van Thiel DH
        • Moore CM
        • Garcia M
        • George M
        • Nadir A
        Continuous peritoneal drainage of large-volume ascites.
        Dig Dis Sci. 2011; 56: 2723-2727
        • Reinglas J
        • Amjadi K
        • Petrcich B
        • Momili F
        • Shaw-Stiffel T
        The palliative management of refractory cirrhotic ascites using the PleurX (©) catheter.
        Can J Gastroenterol Hepatol. 2016; 20164680543
        • Kathpalia P
        • Bhatia A
        • Robertazzi S
        • et al.
        Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites.
        Intern Med J. 2015; 45: 1026-1031
        • Ariza X
        • Castellote J
        • Lora-Tamayo J
        • et al.
        Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis.
        J Hepatol. 2012; 56: 825-832
        • Fiore M
        • Maraolo AE
        • Gentile I
        • et al.
        Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: a systematic review.
        World J Gastroenterol. 2017; 23: 4654-4660
        • Ardolino E
        • Wang SS
        • Patwardhan VR
        Evidence of significant ceftriaxone and quinolone resistance in cirrhotics with spontaneous bacterial peritonitis.
        Dig Dis Sci. 2019; 64: 2359-2367
        • Reuken PA
        • Pletz MW
        • Baier M
        • Pfister W
        • Stallmach A
        • Bruns T
        Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study.
        Aliment Pharmacol Ther. 2012; 35: 1199-1208
        • Fernandez J
        • Acevedo J
        • Castro M
        • et al.
        Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.
        Hepatology. 2012; 55: 1551-1561
        • Ferstl PG
        • Müller M
        • Filmann N
        • et al.
        Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms.
        Infect Drug Resist. 2018; 11: 2047-2061
        • Dever JB
        • Sheikh MY
        Review article: spontaneous bacterial peritonitis–bacteriology, diagnosis, treatment, risk factors and prevention.
        Aliment Pharmacol Ther. 2015; 41: 1116-1131
        • Runyon BA
        • Akriviadis EA
        • Sattler FR
        • Cohen J
        Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis.
        Dig Dis Sci. 1991; 36: 1782-1786
        • Baskol M
        • Gorsoy S
        • Baskol G
        • Ozbakir O
        • Guven K
        • Yucesoy M
        Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients.
        J Clin Gastroenterol. 2003; 37: 403-405
        • Sort P
        • Navasa M
        • Arroyo V
        • et al.
        Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
        N Engl J Med. 1999; 341: 403-409
        • Fernández J
        • Angeli P
        • Trebicka J
        • et al.
        Efficacy of albumin treatmentfor patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis.
        Clin Gastroenterol Hepatol. 2020; 18: 963-973.e14
        • Leão GS
        • John Neto G
        • Jotz RF
        • Mattos AA
        • Mattos ÂZ
        Albumin for cirrhotic patients with extraperitoneal infections: a meta-analysis.
        J Gastroenterol Hepatol. 2019; 34: 2071-2076